Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?

× No keyword cloud information.

19 in total

1. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

Authors: T A Jacobson; G G Griffiths; C Varas; D Gause; J C Sung; C M Ballantyne
Journal: Arch Intern Med Date: 2000-05-08

2. Clofibrate and niacin in coronary heart disease.

Authors:
Journal: JAMA Date: 1975-01-27 Impact factor: 56.272

3. Hy's law.

Authors: Adrian Reuben
Journal: Hepatology Date: 2004-02 Impact factor: 17.425

4. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study.

Authors: P A Sytkowski; W B Kannel; R B D'Agostino
Journal: N Engl J Med Date: 1990-06-07 Impact factor: 91.245

Review 5. Management of hypercholesterolemia.

Authors: D R Illingworth
Journal: Med Clin North Am Date: 2000-01 Impact factor: 5.456

6. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors: T A Pearson; I Laurora; H Chu; S Kafonek
Journal: Arch Intern Med Date: 2000-02-28

Review 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal: Circulation Date: 2004-07-13 Impact factor: 29.690

8. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Authors: Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Journal: Am J Cardiol Date: 2003-07-15 Impact factor: 2.778

9. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245

Review 10. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.

Authors: H Bryan Brewer
Journal: Am J Cardiol Date: 2003-08-21 Impact factor: 2.778

6 in total

Review 1. Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.

Authors: Annalisa Marcuzzi; Elisa Piscianz; Claudia Loganes; Liza Vecchi Brumatti; Alessandra Knowles; Sabrine Bilel; Alberto Tommasini; Roberta Bortul; Marina Zweyer
Journal: Int J Mol Sci Date: 2015-12-30 Impact factor: 5.923

Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?

1. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

2. Clofibrate and niacin in coronary heart disease.

3. Hy's law.

4. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study.

Review 5. Management of hypercholesterolemia.

6. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Review 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

8. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

9. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Review 10. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.

Review 1. Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.

Review 2. Pyridine Dinucleotides from Molecules to Man.

Review 3. Emerging views of statin pleiotropy and cholesterol lowering.

Review 4. Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.

5. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.

Review 6. Human isoprenoid synthase enzymes as therapeutic targets.